Program
KP-100IT
A development code.
Its studies are mostly in Spinal Cord Injuries, led by Kringle Pharma.
Furthest: phase 3, since Jul 12, 20203 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kringle Pharma | 31 open or running | phase 3since Jul 12, 2020 | Jun 27, 2014 | Dec 31, 2028phase 3 · NCT07722962 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2014First study: phase 2 study in Spinal Cord InjuriesFirst studyNCT02193334 · 45 enrolled · Japan
- Jul 12, 2020Phase 3 study in Deafness, Autosomal Recessive 39NCT04475224 · 25 enrolled · Japan
- Jul 20, 2026Phase 3 study in Deafness, Autosomal Recessive 39NCT07722962 · 10 planned · Japan
Ahead
- Dec 31, 2028Primary completion: phase 3 study in Deafness, Autosomal Recessive 39NCT07722962
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722962Deafness, Autosomal Recessive 39 · Japan | 3 | Not yet recruiting | Dec 31, 2028 | 10 |
| NCT04475224Deafness, Autosomal Recessive 39 · Japan | 3 | UNKNOWN | Dec 31, 2022 | 25 |
| NCT02193334Spinal Cord Injuries · Japan | 2 | Completed | Dec 21, 2017 | 45 |
How it is read
Names in the registry
- “KP-100IT”, 3 entries
Codes read as this program: KP100IT.
Conditions, from the studies’ own filings
- Spinal Cord Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.